Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
13.3M
-
Number of holders
-
49
-
Total 13F shares, excl. options
-
2.95M
-
Shares change
-
-1.41M
-
Total reported value, excl. options
-
$19.3M
-
Value change
-
-$7.68M
-
Put/Call ratio
-
0.52
-
Number of buys
-
14
-
Number of sells
-
-23
-
Price
-
$6.54
Significant Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q3 2025
61 filings reported holding KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q3 2025.
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) has 49 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.95M shares
of 13.3M outstanding shares and own 22.22% of the company stock.
Largest 10 shareholders include T. Rowe Price Investment Management, Inc. (701K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (421K shares), VANGUARD GROUP INC (408K shares), BlackRock, Inc. (232K shares), Catalio Capital Management, LP (143K shares), Avidity Partners Management LP (135K shares), MARSHALL WACE, LLP (128K shares), C WorldWide Group Holding A/S (100K shares), GEODE CAPITAL MANAGEMENT, LLC (93.3K shares), and GROUP ONE TRADING LLC (68.4K shares).
This table shows the top 49 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.